skip to Main Content

University of Toronto sperm selection technology featured in the Toronto Star

U of T Logo“In a project spearheaded by PhD candidate Reza Nosrati, U of T researchers are trying to learn more about the way sperm cells move — something that could benefit those using in vitro fertilization (IVF),” writes Daniel Otis in “Sperm show U of T researchers a new trick: slithering” published in the Toronto Star on November 13, 2015.

MaRS Innovation is working with Professor David Sinton, Nosrati and the university’s Innovations and Partnerships Office to commercialize the technology for the human sperm selection markets, including intellectual property strategy and patent filing, and securing industry partners and collaborators.

Continue Reading

Triphase secures FDA orphan drug designation for Marizomib in Malignant Glioma

MI_triphaseTORONTO and SAN DIEGO (November 19, 2015) — Triphase Accelerator Corporation, a private drug development company dedicated to advancing novel compounds through Phase 2 proof-of-concept, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for marizomib to treat patients with malignant glioma.

Malignant glioma is an aggressive form of brain cancer for which there is a significant unmet need in current treatments due to the disease’s poor prognosis. Triphase is evaluating marizomib, a novel and highly potent proteasome inhibitor, in combination with bevacizumab in patients with recurrent glioblastoma.

Orphan drug designation is granted by the FDA Office of Orphan Products Development (OOPD) to novel drugs or biologics that treat a rare disease or condition affecting fewer than 200,000 patients in the United States.

Continue Reading

Flybits named to Deloitte’s Technology Fast 50 Companies to Watch

FFlybits Corporate Logo Nov 2015lybits, a Ryerson University start-up company created in partnership with MaRS Innovation, has been named to Deloitte‘s Technology Fast 50 Companies to Watch list.

According to TechVibes, “Companies were selected for their technological innovation, entrepreneurship, leadership and growth. Now in its 18th year, Technology Fast 50 celebrated companies with an average four-year growth rate of 1,293%.”

You can read TechVibes’ coverage of the Deloitte announcement here. The full list, of which 62% are software companies, is posted on Deloitte’s website.

Continue Reading

UTEST cited among Toronto’s top 10 tech accelerators

MI_utestUTEST, the tech accelerator co-directed by MaRS Innovation and the University of Toronto, was named to BlogTO‘s Top 10 list of technology accelerators on November 8, 2015.

The list was published just weeks before the announcement of the fourth UTEST cohort, and included recognition of TrendMD and Whirlscape as notable startups among the graduated UTEST companies.

Here’s the excerpt:

UTEST, a collaboration between U of T and MaRs Innovation, is in its fourth year of operation with 15 teams. The program is one year in length and is only available to current students, recent grads and university faculty. UTest invests $30,000 in its companies in return for 5% equity. Two notable alumni are scholarly content recommendation engine TrendMD and mobile keyboard creator Whirlscape.

The article also mentions Slyce as a breakout company from the INCubes accelerator; the company acquired York University technology through a license deal negotiated by MaRS Innovation prior to their IPO.

Continue Reading
Back To Top